Queen Mary University of London spin-out Activiomics enters into research programme with Kyowa Hakko Kirin.
Life sciences firm Activiomics has built on its contract research agreement with Japan-based pharmaceutical firm Kyowa Hakko Kirin (KHK) by entering into a new research programme. The London-based Queen Mary University of London spin-out will apply its cell signalling TIQUAS platform to lead compounds supplied by KHK. Activiomics has received $805k in venture funding. The…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
